Webinar 1: Identifying Patients at High Risk for Fractures
Release Date: April 1, 2010
Expiration Date: April 1, 2013
INSTRUCTIONS FOR OBTAINING CME/CE/CEU CREDIT
There are no fees or prerequisites for participating in and receiving CME/CE/CEU
credit for this online educational activity. In order to obtain CME/CE/CEU
credit for participating in this activity during the period of April 1,
2010, through April 1, 2013, participants must (1) read the educational
objectives and disclosure statements; (2) study the educational activity; (3)
complete the online learning assessment, scoring 70% or higher; (4) complete the
evaluation; and (5) submit the evaluation form online to the Institute. This
activity should take approximately 1 hour to complete.
A statement of credit will be issued only upon receipt of a post-test with a
score of 70% or higher and a completed activity evaluation. After submitting
these forms, you will be able to print out your CME/CE/CEU certificate.
STATEMENT OF NEED
Osteoporosis is a common skeletal disease characterized by compromised bone
strength that predisposes individuals to an increased risk of fracture. In the
United States alone, osteoporosis affects more than 10 million individuals aged
50 years and older. Due to the aging population, that number is expected to
reach 14 million by 2020. An additional 30 million Americans have osteopenia, or
low bone mass, and are at risk for developing osteoporosis.
Despite widely-disseminated guidelines from the National Osteoporosis Foundation
and the American Association of Clinical Endocrinologists regarding prevention,
screening, and treatment of osteoporosis, studies indicate that patients are not
receiving the recommended level of care. Even after sustaining an
osteoporosis-related fracture, most patients are not diagnosed or treated for
the condition. Additionally, significant discrepancies exist between practices
in osteoporosis patient management. Standardizing the level of care is paramount
to ensure optimal patient outcomes.
Learning Objectives:
At the conclusion of this program, the learners will be able to:
- Identify common risk factors for osteoporosis and osteoporotic fracture in men and women
- Describe benefits and limitations of FRAX and other fracture risk assessment tools
- Appropriately evaluate secondary causes of osteoporosis
- Assess the applicability of National Osteoporosis Foundation guidelines for densitometry and risk assessment, calcium and vitamin D, and exercise
ACPE Activity Type: Knowledge-based
TARGET AUDIENCE
The target audience for these activities includes rheumatologists, rheumatology
nurses, endocrinologists, obstetricians/gynecologists (Ob/Gyn’s), pharmacists,
and other healthcare professionals who have an interest in the treatment and
management of osteoporosis.
Webinar 2: Optimizing Therapy: Current and Emerging Treatment Options for Osteoporosis
Release Date: June 15, 2010
Expiration Date: June 15, 2013
INSTRUCTIONS FOR OBTAINING CME/CE/CEU CREDIT
There are no fees or prerequisites for participating in and receiving CME/CE/CEU
credit for this online educational activity. In order to obtain CME/CE/CEU
credit for participating in this activity during the period of June 15,
2010, through June 15, 2013, participants must (1) read the educational
objectives and disclosure statements; (2) study the educational activity; (3)
complete the online learning assessment, scoring 70% or higher; (4) complete the
evaluation; and (5) submit the evaluation form online to the Institute. This
activity should take approximately 1 hour to complete.
A statement of credit will be issued only upon receipt of a post-test with a
score of 70% or higher and a completed activity evaluation. After submitting
these forms, you will be able to print out your CME/CE/CEU certificate.
STATEMENT OF NEED
Osteoporosis is a common skeletal disease characterized by compromised bone
strength that predisposes individuals to an increased risk of fracture. In the
United States alone, osteoporosis affects more than 10 million individuals aged
50 years and older. Due to the aging population, that number is expected to
reach 14 million by 2020. An additional 30 million Americans have osteopenia, or
low bone mass, and are at risk for developing osteoporosis.
Despite widely-disseminated guidelines from the National Osteoporosis Foundation
and the American Association of Clinical Endocrinologists regarding prevention,
screening, and treatment of osteoporosis, studies indicate that patients are not
receiving the recommended level of care. Even after sustaining an
osteoporosis-related fracture, most patients are not diagnosed or treated for
the condition. Additionally, significant discrepancies exist between practices
in osteoporosis patient management. Standardizing the level of care is paramount
to ensure optimal patient outcomes.
Learning Objectives:
At the conclusion of this program, the learners will be able to:
- Evaluate recent recommendations for the use of nonpharmacologic agents such as
vitamin D, calcium, and exercise in patients with osteoporosis
- Develop a plan to address high-profile patient concerns such as subtrochanteric
fractures of the femoral shaft, osteonecrosis of the jaw, and osteosarcoma
related to pharmacologic agents frequently used to treat osteoporosis
- Discuss data that supports current unmet needs in the treatment of patients with
osteoporosis
- Explain the potential role of late-stage pipeline agents under investigation for
the treatment of osteoporosis
ACPE Activity Type: Knowledge-based
TARGET AUDIENCE
The target audience for these activities includes rheumatologists, rheumatology
nurses, endocrinologists, obstetricians/gynecologists (Ob/Gyn’s), pharmacists,
and other healthcare professionals who have an interest in the treatment and
management of osteoporosis.
Webinar 3: Clinical Challenges in the Management and Treatment of Osteoporosis
Release Date: August 15, 2010
Expiration Date: August 15, 2013
INSTRUCTIONS FOR OBTAINING CME/CE/CEU CREDIT
There are no fees or prerequisites for participating in and receiving CME/CE/CEU
credit for this online educational activity. In order to obtain CME/CE/CEU
credit for participating in this activity during the period of August 23,
2010, through August 23, 2013, participants must (1) read the educational
objectives and disclosure statements; (2) study the educational activity; (3)
complete the online learning assessment, scoring 70% or higher; (4) complete the
evaluation; and (5) submit the evaluation form online to the Institute. This
activity should take approximately 1 hour to complete.
A statement of credit will be issued only upon receipt of a post-test with a
score of 70% or higher and a completed activity evaluation. After submitting
these forms, you will be able to print out your CME/CE/CEU certificate.
STATEMENT OF NEED
Osteoporosis is a common skeletal disease characterized by compromised bone
strength that predisposes individuals to an increased risk of fracture. In the
United States alone, osteoporosis affects more than 10 million individuals aged
50 years and older. Due to the aging population, that number is expected to
reach 14 million by 2020. An additional 30 million Americans have osteopenia, or
low bone mass, and are at risk for developing osteoporosis.
Despite widely-disseminated guidelines from the National Osteoporosis Foundation
and the American Association of Clinical Endocrinologists regarding prevention,
screening, and treatment of osteoporosis, studies indicate that patients are not
receiving the recommended level of care. Even after sustaining an
osteoporosis-related fracture, most patients are not diagnosed or treated for
the condition. Additionally, significant discrepancies exist between practices
in osteoporosis patient management. Standardizing the level of care is paramount
to ensure optimal patient outcomes.
Learning Objectives:
At the conclusion of this program, the learners will be able to:
- Evaluate the importance of specific risk factors such as age, gender, and race
on the overall development of osteoporosis
- Discuss the impact of low vitamin D levels in patients with osteopenia and
osteoporosis
- Develop strategies to combat common reasons for nonadherence to bisphosphonate
therapy
- Determine specific circumstances where a drug holiday may or may not be
appropriate in patients being treated for osteoporosis for more than 5 years
ACPE Activity Type: Knowledge-based
TARGET AUDIENCEE
The target audience for these activities includes rheumatologists, rheumatology
nurses, endocrinologists, obstetricians/gynecologists (Ob/Gyn’s), pharmacists,
and other healthcare professionals who have an interest in the treatment and
management of osteoporosis.
EDUCATIONAL PLANNING COMMITTEE:
 |
Neal S. Birnbaum, MD
Director, Division of Rheumatology
California Pacific Medical Center
Clinical Professor of Medicine
University of California, San Francisco
San Francisco, California
 |
|
|
|
 |
Steven Ron Cummings, MD, FACP
Founding Director, San Francisco Coordinating Center
Professor of Medicine and Epidemiology & Biostatistics (Emeritus)
University of California, San Francisco
Director of Clinical Research
California Pacific Medical Center Research Institute
San Francisco, California
|
|
|
|
 |
E. Michael Lewiecki, MD, FACP, FACE
Osteoporosis Director
Clinical Research & Osteoporosis Center, Inc.
Albuquerque, New Mexico
|
|
|
|
Linda Wilson, RN, PhD, CPAN, CAPA, BC, CNE
Assistant Dean for Special Projects and Programs
Drexel University College of Nursing and Health Professionals
Philadelphia, Pennsylvania
Christine M. O'Leary, PharmD, BCPS
Director, Clinical Services
Institute for Continuing Healthcare Education
Adjunct Pharmacy Practice Faculty
University of the Sciences in Philadelphia
Philadelphia, Pennsylvania
All faculty for these continuing education activities are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
FACULTY DISCLOSURE INFORMATION
It is the policy of the Institute for Continuing Healthcare Education (the Institute) that the education presented at Institute-provided, CME/CE/CEU-certified activities be unbiased and based upon scientific evidence. To help participants make judgments about the presence of bias, the Institute provides information that faculty have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this educational activity. Any relationships faculty members may have with commercial entities have been disclosed and reviewed, and any potential conflicts have been resolved.
Relationships are abbreviated as follows: A, Advisor/review panel member; C, Consultant; G, Grant/research support recipient; E, Education planning committee; H, Honoraria; PE, Promotional event talks; S, Stock shareholder; SB, Speakers’ Bureau; O, Other.
Neal S. Birnbaum, MD, has disclosed the following relevant financial relationships that have occurred within the past 12 months: UCB, Amgen, Wyeth/A, SB; Centocor, URL Pharma, Inc. /A; Abbott Laboratories/SB.
Steven Ron Cummings, MD, FACP, has disclosed the following relevant financial relationships that have occurred within the past 12 months: Amgen, Eli Lilly and Company/C, H; Novartis/H.
Debra Dreger (Medical Writer – Webinar 1) disclosed that she has not had any relevant financial relationships that have occurred within the past 12 months.
Kathy Holliman (Medical Writer – Webinar 2 & 3) has disclosed that she has not had any relevant financial relationships that have occurred within the past 12 months.
E. Michael Lewiecki, MD, FACP, FACE has disclosed the following relevant financial relationships that have occurred within the past 12 months: Eli Lilly and Company, Novartis, Hoffman-La Roche Ltd./A, G, SB; Amgen, Wyeth/A, G; Procter & Gamble/G, S; GlaxoSmithKline, Pfizer, Sanofi-aventis/G; Upsher-Smith/S; General Electric, Teva Pharmaceutical Industries Ltd./S
Linda Wilson, RN, PhD, CPAN, CAPA, BC, CNE, has disclosed that she has not had any relevant financial relationships that have occurred within the past 12 months.
Stanford L. Peng, MD, (Peer Reviewer) has disclosed the following relevant financial relationship that has occurred within the past 12 months: UCB/A.
ACTIVITY DEVELOPMENT TEAM
Cathy Pagano, CCMEP, John Torba, Christine M. O'Leary, PharmD, BCPS, Scott Kober, CCMEP, Karen J. Thomas, CCMEP, Sandra Davidson, and Courtney Cohen are employees of the Institute for Continuing Healthcare Education and are collectively responsible for the planning, development, management, and evaluation of this CME/CE/CEU activity. Kathy Holliman and Debra Dreger are Medical Writers and are independent contractors. These individuals have disclosed that they have had no relevant financial relationships specific to the subject matter of this activity that have occurred within the past 12 months. Shunda R. Irons-Brown, PhD, MBA, also an employee of the Institute, has disclosed the following relationships: Merck & Co./SS; Bristol-Myers Squibb, GlaxoSmithKline/O.
Dr. John Ruggiero, past employee of the Institute, was involved in the development of the first activity,
Webinar 1: “Identifying Patients at High Risk for Fractures,” during his tenure. Dr. Ruggiero has disclosed that he has not had any relevant financial relationships specific to the subject matter of this activity that occurred within the past 12 months prior.
OFF-LABEL/INVESTIGATIONAL USE DISCLOSURE
Webinar 1: “Identifying Patients at High Risk for Fractures” activity content does not include discussions regarding the off-label or investigational use of any drugs or devices.
Webinar 2: “Optimizing Therapy: Current and Emerging Treatment Options for Osteoporosis “activity content includesdiscussion on off-label and investigational uses of denosumab and odanacatib.
Webinar 3: “Clinical Challenges in the Management and Treatment of Osteoporosis” activity content does not include discussions regarding the off-label or investigational use of any drugs or devices.
ACCREDITATION STATEMENTS
PHYSICIANS
The Institute for Continuing Healthcare Education (the Institute) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Institute designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
PHARMACISTS
The Institute for Continuing Healthcare Education is accredited by the
Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing
pharmacy education. This program is acceptable for 1.0 hour (0.1 CEU) of
continuing education credit in states that recognize ACPE accredited providers.
All faculty for these continuing education activities are competent in the subject matter and qualified by experience, training and/or preparation to the tasks and methods of delivery .
Webinar 1: “Identifying Patients at High Risk for Fractures” - ACPE ID# 0781-0000-10-001-H01-P.
Webinar 2: “Optimizing Therapy: Current and Emerging Treatment Options for Osteoporosis”- ACPE ID# 0781-0000-10-002-H01-P.
Webinar 3: “Clinical Challenges in the Management and Treatment of Osteoporosis”
- ACPE ID# 0781-0000-10-003-H01-P.
In order to receive a statement of credit, participants will need to complete the online activity as well as the entire post-activity learning assessment and activity evaluation form while receiving a score of 70% or greater. Only completed tests are eligible for credit; no partial or incomplete tests will be processed. No partial credit will be awarded for this online learning web based CPE activity. Pharmacists should note that they are required to participate in the activity in its entirety to be eligible for credit. Pharmacists should only claim the CEUs commensurate with the extent of their participation in the activity.
Statements of credit will be available immediately upon completion of the activity and achievement of a passing score of 70% or greater. There is no fee required to participate in this online educational activity.
NURSES
Institute for Continuing Healthcare Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC-COA).
This activity offers 1.0 contact hours to participating nurses. This credit may be applied toward licensure requirements in those states that recognize ANCC-COA accredited providers.
Accreditation applies solely to educational activities and does not imply approval or endorsement of any commercial product by ANCC-COA.
CALIFORNIA BOARD OF NURSING
The Institute for Continuing Healthcare Education is approved by the California Board of Registered Nursing, Provider Number 13313.
The Institute for Continuing Healthcare Education approves this activity for 1.2 contact hours.
Linda Wilson, RN, PhD, CPAN, CAPA, BC, CNE, is the recognized, designated nurse planner for this activity.
For questions regarding the content of this CME/CE/CEU activity, contact the accredited provider, the Institute for Continuing Healthcare Education, Melissa M. Schepacarter, CMP, at 215-446-8088 ext. 1116 or via email at mschepacarter@iche.edu.
GENERAL DISCLOSURE AND COPYRIGHT
The opinions expressed within this activity are those of the participating faculty and not those of the Institute for Continuing Healthcare Education, Amgen Inc., sanofi-aventis, Eli Lilly and Company, or any manufacturers of products mentioned herein.
The information is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a healthcare professional relative to diagnostic and treatment options of a specific patient’s medical condition. In no event will the Institute for Continuing Healthcare Education be responsible for any decision made or action taken based upon the information provided through this activity.
Participants are encouraged to consult the package insert for all products for updated information and changes regarding indications, dosage, and contraindications. This recommendation is particularly important with new or infrequently used products.
Copyright 2010, Institute for Continuing Healthcare Education (the Institute). All rights reserved. No part of this presentation may be reproduced or transmitted in any other form or by any means, electronic or mechanical, without first obtaining written permission from the Institute. These webinars have been provided as an educational service of the Institute for Continuing Healthcare Education (the Institute) and supported by educational grants from Amgen Inc., sanofi-aventis, and Eli Lilly and Company.
Contact information for technical assistance: Click here
If you have any trouble with this registration site, please contact the Institute for Continuing Healthcare Education at group_meetings_ICHE@ICHE.edu or call 215-446-8088, ext 1116.